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A B S T R A C T
Background: Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the decarboxylation of oxaloacetate to
phosphoenolpyruvate. The mitochondrial isozyme, PEPCK-M is highly expressed in cancer cells, where it plays a
role in nutrient stress response. To date, pharmacological strategies to target this pathway have not been pur-
sued.
Methods: A compound embodying a 3-alkyl-1,8-dibenzylxanthine nucleus (iPEPCK-2), was synthesized and
successfully probed in silico on a PEPCK-M structural model. Potency and target engagement in vitro and in vivo
were evaluated by kinetic and cellular thermal shift assays (CETSA). The compound and its target were validated
in tumor growth models in vitro and in murine xenografts.
Results: Cross-inhibitory capacity and increased potency as compared to 3-MPA were confirmed in vitro and in
vivo. Treatment with iPEPCK-2 inhibited cell growth and survival, especially in poor-nutrient environment,
consistent with an impact on colony formation in soft agar. Finally, daily administration of the PEPCK-M in-
hibitor successfully inhibited tumor growth in two murine xenograft models as compared to vehicle, without
weight loss, or any sign of apparent toxicity.
Conclusion: We conclude that iPEPCK-2 is a compelling anticancer drug targeting PEPCK-M, a hallmark gene
product involved in metabolic adaptations of the tumor.
1. Background
Phosphoenolpyruvate carboxykinase (PEPCK) (GTP; EC 4.1.1.32)
catalyzes the GTP-dependent conversion of oxaloacetate (OAA) to
phosphoenolpyruvate (PEP) from two very similar isozymes localized to
the cytosol (PEPCK-C) or the mitochondria (PEPCK-M) [1,2], and
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encoded by different nuclear genes (PCK1 and PCK2, respectively).
Interestingly, both isozymes are differentially expressed and regulated.
Whereas PEPCK-C is restricted to gluconeogenic and glyceroneogenic
tissues (liver, small intestine, kidney cortex, and adipose tissue), and
responds to insulin, glucagon and dexamethasone, PEPCK-M mRNA
content is not regulated by hormonal cues, but it is more widely ex-
pressed (i.e., T- and B-cells, pancreatic β-cells, liver, neurons, and un-
differentiated tissues such as embryonal stem cells and tumors) [3–8].
In differentiated tissues PEPCK-M role is not completely understood,
although it clearly impinges on cataplerosis and TCA cycle flux in the
liver [6], and pancreatic β-cells [5].
In tumor cells, on the other hand, this enzyme promotes amino-acid
homeostasis, 1-carbon metabolism and several biosynthetic processes
crucial to sustain cancer cell and neuroprogenitor metabolism [8–10].
Indeed, the gene encoding for PEPCK-M, PCK2, is a target for ATF4, the
master regulator of ER- and amino-acid stress responses [7]. PEPCK-M
protein and mRNA was upregulated by effectors of this pathway by
recruiting ATF4 to a consensus AARE site located at the PCK2 proximal
promoter. Consistently, knocking-down PEPCK-M under stress tipped
the balance of the cell towards apoptosis, whereas overexpressing
PEPCK-M enhanced cell survival [7]. The importance of chronic ER-
stress to induce adaptive responses in cancer cells in vivo suggested that
the pathway is crucial to cancer cell metabolism and progression. In
agreement with this view, loss-of-function genetic models have shown
the relevance of PEPCK-M in cell growth and chemoresistance in lung
and colon cancer, respectively [10–12].
Thus, we have aimed to identify the potential for this pathway in
cancer therapeutic intervention by evaluating a small molecule tar-
geting this enzyme, and its pharmacological validation in a murine
preclinical cancer indication. A compound embodying a 3-alkyl-1,8-
dibenzylxanthine skeleton previously described as GTP competitive
inhibitor for PEPCK-C [13] in an in vitro assay, was retargeted against
PEPCK-M and systematically assessed for target engagement, efficacy in
vitro, and pharmacokinetics and activity in vivo. PEPCK-M inhibition
leads to metabolic imbalances comparable to down-regulation of the
enzyme using genetic models (i.e., CRISPR/cas9), hindering cell viabi-
lity in vitro and in xenograft models of transformed embryonal kidney
(HEK-293) and colon carcinoma (SW-480) tumor growth. Therefore, we
conclude that the PEPCK-M inhibitor described here have potent an-




The details of the synthesis and characterization of iPEPCK-2 are
given in Methods S1 in Supporting Information.
2.2. Computational protocol
Pairwise sequence alignment for PEPCK-C and PEPCK-M isoforms
was performed using stretcher (https://www.ebi.ac.uk/Tools/psa/; see
Fig. S2 in Supporting Information). The PDB structure of human
PEPCK-C co-crystallized with the GDP-competitive inhibitor, N-(4-{[3-
butyl-1-(2-fluorobenzyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl]
methyl}phenyl)-1-methyl-1H-imidazole-4-sulfonamide (PDB ID:
2GMV) [13] was used as a template to generate the protein model for
PEPCK-M with Swissmodel [14]. Choice of this X-ray structure was
motivated by the high resemblance between the crystallographic ligand
and iPEPCK-2.
AutoDock4 [15] was used to dock iPEPCK-2 in PEPCK-M generated
by homology modeling from the cytosolic isoform. A structural water
molecule (wat740 in 2GMV), mediating ligand interactions with pro-
tein residues W527 and W516, was included in the PEPCK-M structure,
and its position was determined upon alignment of the 3D structures of
the homology model built for PEPCK-M and the reference PDB (2GMV)
structure. A grid spacing of 0.375 Å was used in conjunction with
62× 62×62 grid points to define the box considered to explore the
arrangement of the ligand in the binding pocket. A genetic algorithm
was used to guide the docking search during pose generation. A total of
30 docking conformations were finally generated and analyzed.
2.3. Recombinant human PEPCK-C and PEPCK-M
Open reading frames from human PCK1 coding for PEPCK-C and
PCK2 coding for PEPCK-M were cloned and transferred to the pET15b
vector, and competent BL21 E. coli cells were transformed with the
expression construct. Cells were precultured in 10mL of 2xYT over-
night, and the next day were grown at 37 °C in 200mL of 2xYT medium
until they grew to an optical density of 0.5-0.6 at λ600. Then, IPTG was
added to a final concentration of 1mM to induce protein expression.
The cells were incubated at room temperature for 5 h under moderate
shaking (110 rpm). PEPCK-M was produced and isolated from Arctic
express E. coli cells as described [16].
Cells were harvested by centrifugation and resuspended in lysis
buffer, then lysozyme was added, and the mix was incubated 30min in
ice. The suspension was sonicated on ice for six cycles of 10 s ON and
30 s OFF. Then, DNAse was added, and after 15min incubation, the cell
debris was removed by centrifugation and the supernatants were pur-
ified using Qiagen Ni-NTA Agarose following the manufacturer pro-
tocol. The purified enzymes were used immediately or stored at −80 °C
until needed.
2.4. PEPCK activity assays
Kinetic assays were performed analyzing NADH consumption by
spectrophotometry. Absorbance was measured at 340 nm during 6min
at 37 °C in a total volume of 1mL. The following reaction was studied in
the presence of different concentrations of PEPCK inhibitors:
PEP+CO2 + GTP (PEPCK) →GDP+OAA+NADH (MDH) →
MA+NAD+
The reaction was performed in 50mM Tris-HCl (pH 7.4), 20mM
NaHCO3, 1mM MnCl2, in the presence of CO2 (carbogen infusion for
10min). Then the following components were added: 0.5mM PEP,
0.1 mM NADH, 2 UI/mL Malate dehydrogenase (MDH), 5 μM rotenone,
25mM DTT. Recombinant PEPCK-C or PEPCK-M and the inhibitors
were then added, and the reaction started by the addition of 0.2 mM of
GDP.
2.5. Cell culture
All cell lines, except otherwise indicated, were grown in DMEM
medium supplemented with 10% of fetal bovine/calf serum, 100 IU/mL
penicillin + 100 μg/mL streptomycin, and 2mM glutamine. INS-1 rat
insulinoma cells were grown in complete RPMI-1640 supplemented
with 71 μM of β-mercaptoethanol. For glucose deprivation experiments
cells were seeded with glucose-free DMEM, and it was supplemented
with 10% of dialyzed FBS, 100 IU/mL penicillin + 100 μg/mL strep-
tomycin, and 2mM glutamine.
2.6. Cellular thermal shift assay (CETSA)
Intact and viable mouse embryonal fibroblast (MEF) cells were
harvested and resuspended to a final concentration of 2×106 cells/mL.
Different PEPCK-M inhibitors were added to this suspension, to a final
concentration of 5 μM, and incubated for 30min at 37 °C. Cells were
washed and resuspended with PBS to a final concentration of 3× 107
cells/mL. They were split in different tubes and treated with a gradient
of temperatures between 40 and 60 °C for 3min, cells were incubated
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3min at room temperature and snap frozen with liquid nitrogen. Cells
were lysed using a freeze/thaw cycle with liquid nitrogen and cen-
trifuged at 20000 g 20min at 4 °C. Finally, stable PEPCK-M present in
the supernatant was quantified by western blot.
The analysis was also performed treating the cells with a gradient of
PEPCK-M inhibitor concentrations and a thermal treatment at a single
temperature (60 °C). IsoThermal Dose-Response Fingerprint (ITDRFCE-
TSA) concentrations were calculated as described [17].
2.7. Cell viability and anchorage-independent growth
Proliferation assays were performed on MCF7, HEK-293, HCT-116
and SW-480 cells seeded at 5×103 cells/well in 96-well plates. After
overnight incubation cells were treated with the different PEPCK in-
hibitors between 24 and 72 h. Then viability was measured by MTT.
Anchorage-independent growth capacity was tested counting the
colonies formed when cells have been seeded in soft agar. Firstly, the
wells of 6-well plates were filled with 2mL of complete medium with
0.6% melted agar. When agar solidified, 105 cells were seeded in 1mL
of complete medium (DMEM) with 0.3% agar with or without PEPCK-M
inhibitors. Once the superior layer solidified, 500 μL of treatment
medium was renewed, and changed twice a week. The plate was in-
cubated for two weeks, and the colonies were stained with MTT and
counted.
2.8. Glucose-stimulated insulin secretion (GSIS)
Insulin secretion experiments were performed in INS-1 rat in-
sulinoma cells and fasted ICR mice. GSIS in INS1 cells; four hundred
thousand cells/well were seeded in a 24 well and incubated with
2.8 mM of glucose KRBH medium in the presence or absence of iPEPCK-
2 for 2 h. Then, the medium was discarded and 500 μL of KRBH medium
with 2.8 mM of glucose were added for 1 h. Next, supernatants were
collected and incubated in 500 μL of KRBH medium with 16.7 mM of
glucose for 1 h. Finally, cells were lysed with RIPA and total protein was
quantified for normalization. GSIS in fasted ICR mice; a GSIS assay was
performed in male ICR white mice between 30 and 40 g (at least n= 4
per group given that insulin concentrations are quite dispersed in the
population at baseline) and all animals were randomized to either the
experimental and control groups. A single intraperitoneal dose of
iPEPCK-2 (dissolved in 40 % PEG 400 in physiological saline), was
administered at the described doses in the morning (between 8 and 10
a.m.) without anesthesia. Later (2 h or 5 h), a bolus of glucose (2 g/kg)
was administered via IP to induce insulin secretion. Mice were mon-
itored for signs of pain or distress during the time between either in-
jection and euthanasia (at the earliest time of 15min and the latest at
1 h after glucose bolus injection). Blood (50 μL) was collected from the
tail vein after incision at the stated time points, and animals were
subsequently sacrificed by cervical dislocation. The content of insulin of
the different supernatants (basal in 2.8 mM glucose, or GSIS in 16.7mM
glucose) was measured by ELISA using theMercodia Mouse Insulin ELISA
kit.
2.9. Pharmacokinetics
The pharmacokinetic study was carried on in male ICR white mice
between 30 and 40 g (n=4 per group, which is a small cohort based on
the potency of the analytical and quantification techniques utilized)
and all animals were randomized to either the experimental and control
groups. A single intraperitoneal dose of iPEPCK-2 (dissolved in 40 %
PEG 400 in physiological saline), was administered at 8mg/kg early in
the morning (between 8 and 10 a.m.) without anesthesia. Mice were
monitored for signs of pain or distress during the time between injec-
tion and euthanasia (at the earliest time of 15min and the latest at 8 h
after injection) and sacrificed by cervical dislocation for blood and
brain collection. Brain and plasma were immediately frozen at -80 °C
for pK analysis. iPEPCK-2 was extracted from plasma and homogenate
brain in PBS with acetonitrile, in the presence of 1M DTT and quan-
tified by HPLC/UV. The solid phase was C18 RP column (5m,
20× 0.4 cm; Kromasil 100; Teknokroma) and the mobile phase con-
sisting in a 0.05M KH2PO4 (45%): acetonitrile (55%). The elution time
of iPEPCK-2 was 3.7min, and it was detected at 290 nm. The assay had
a range of 0.125–5 μg/mL. Calibration curves were constructed by
plotting the peak area ratio of analyzed peak against known con-
centrations.
iPEPCK-2 plasma concentrations versus time curves for the mean of
animals were analyzed by a non-compartmental model based on sta-
tistical moment theory using the “PK Solutions” computer program. The
pharmacokinetic parameters calculated were the area under the con-
centration vs time curve (AUC), which was calculated using the trape-
zoidal rule in the interval 0–8 h, and the half-life (t1/2β), which was
determined as ln2/β (β was calculated from the slope of the linear,
least-squares regression line). The Cmax and Tmax were read directly
from the mean concentration curves.
2.10. Xenograft subcutaneous models
Two subcutaneous tumor xenograft models were generated by in-
jecting transformed cells in both flanks of female 5–6-week-old BALB/c
nude mice (at least n= 5 per group, given the large dispersion on the
size of the tumors grown in flanks of immunocompromised mice). In the
first model, 1× 106 HEK-293 cells were injected per flank; whereas on
the colon carcinoma model, 5× 106 SW-480 cells were utilized.
Handling for the injections was in the absence of anesthesia or an-
algesia, and no signs of distress or pain were evident afterwards. Mice
were monitored for signs of cancer disease, pain or distress during the
time of the experiment and sacrificed by cervical dislocation and re-
moved from the experiment if so advised by the Veterinarian in charge
of the animal facility. When the tumors grew enough to be measured,
mice were randomly split in two groups, and kept in grouped cages of at
least 4 animals per cage. One group received a daily (between 8 and 10
a.m.) IP injection with 8mg/kg of iPEPCK-2 without analgesia. No signs
of distress or pain resulted from the injection. The other group was
treated with vehicle (20% PEG400. 5% DMSO, H2O) instead, following
the same therapeutic regimen. The tumors were measured, and mice
weighted twice a week. After 15 days (SW-480) or 24 days (HEK-293),
mice were euthanized by cervical dislocation, and the tumors and or-
gans processed for further analysis.
2.11. Histopathology
Tissues were fixed twelve hours in 4% Paraformaldehyde Buffer
after trimming them into appropriate size and shape and placing them
in histology cassettes. They were then dehydrated following an ethanol
gradient process and embedded in paraffin. Tissue sections (3–4 μM)
were stained with Harris hematoxylin & eosin stain for morphological
analysis.
2.12. Statistics and data analysis
Cohort size (greater than 5 per group) for all experiments were
based on statistical power calculations using GraphPad Prizm. Animals
studies were not replicated to avoid utilization of additional animals
and given that a sufficient number of animals in each group was utilized
to provide good statistical power. All data was analyzed for variance
and represented as means ± standard error of the mean (SEM) for at
least 3 independent experiments with 3–8 replicates per group. One-
way analysis of the variance (ANOVA) was utilized to unmask sig-
nificant differences, and a Sidak multiple comparison test was used
when indicated in assays containing more than two group comparisons.
Minimum statistical significance was set at *p < 0.05.
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3. Results
3.1. iPECK-2 is a potent on-target inhibitor of PEPCK-M with drug-like
characteristics
We prepared and fully characterized (see Methods S1) 5-chloro-N-
{4-[(3-(cyclopropylmethyl)-1-(2-fluorobenzyl)-2,6-dioxo-2,3,6,9-tetra-
hydro-1H-purin-8-yl)methyl]phenyl}-1,3-dimethyl-1H-pyrazole-4-sul-
fonamide (iPEPCK-2; chemical structure in Fig. S1 in Supporting
Information) previously described by Pietranico et al. as a potent in-
hibitor of PEPCK-C [13].
The PDB structure of human PEPCK-C co-crystallized with a GTP-
competitive inhibitor (PDB ID: 2GMV), was used as template to gen-
erate the structural model of PEPCK-M, taking advantage of the high
sequence identity (69 %) and similarity (82 %) between the two iso-
forms (see Fig. S2 in Supporting Information). Superposition of the
reference PDB structure for PEPCK-C, and the homology model built for
PEPCK-M is shown in Fig. 1A. This comparison highlighted the pre-
servation of residues in the binding pocket, and a few differences in
residues around the edges of the pocket filled by the crystallographic
ligand. Among them, K342T, K524H, K529R, and G570R are located at
less than 8 Å from the ligand in the GDP-binding site. Autodock4 was
used to dock iPEPCK-2 in the GDP-binding site of PEPCK-M. The two
most interesting docking poses found for iPEPCK-2 are reported in
Fig. 1B and C. The xanthine moiety is stably placed in a sub-cavity
surrounded by N292, W516, F525, W527, and F530. The two oxygen
atoms participate in hydrogen-bonding interactions with N292 and
N533. Water-mediated polar interactions are also observed between the
protonated nitrogen of the xanthine scaffold and the backbone oxygens
of W527 and W516. The 2 F-benzene is inserted in a subpocket and
stabilized by hydrophobic interactions with L293 and M296 (not
shown). Two different orientations were, however, found for the pyr-
azole-4-sulfonamide moiety. In one case (Fig. 1B), this fragment mat-
ches the arrangement found in the crystallographic ligand in 2GMV,
which involves the stacking of the pyrazole ring with F530. In the
second case (Fig. 1C), a key difference in the vicinity of the binding
pocket is the sulfonamide group interaction exclusive for the guanidine
moiety of R570 in PEPCK-M (G570 in PEPCK-C).
Before evaluating iPEPCK-2 as an on-target inhibitor of PEPCK-M in
vitro and in vivo, we performed basic ADMET and pharmacokinetic
studies. In vitro ADMET assays showed good human and murine mi-
crosomal stability with a half-life of 119min and a 75% of compound
Fig. 1. Docking and pharmacokinetics (A)
Superposition of human PEPCK-C (PDB ID:
2GMV; grey) and human PEPCK-M (in cyan).
Changes in residue content at/around the
binding pocket are highlighted, and the crys-
tallographic pose of the inhibitor (N-(4-{[3-
butyl-1-(2-fluorobenzyl)-2,6-dioxo-2,3,6,7-tet-
rahydro-1H-purin-8-yl]methyl}phenyl)-1-me-
thyl-1H-imidazole-4-sulfonamide) is shown as
sticks. (B, C) Representative docking poses for
iPEPCK-2 (in cyan) in the GDP-binding site.
The reference crystallographic protein-ligand
complex (PDB ID: 2GMV) is shown in grey. The
G570R mutation is highlighted in cyan/blue.
Numbering of residues based on the sequence
of PEPCK-C. (D) Plasma concentration of
iPEPCK-2 at various times (15min to 8 h) after
an intraperitoneal administration of 8mg/kg,
as determined by HPLC/UV-VIS at 290 nm.
Basic pharmacokinetic parameters are shown
(in-chart panel). Data are means ± SEM
(n=4 in each time point for panel D).
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remaining after 60min in mice microsomes, predicting good in vivo
pharmacokinetics (see Table S1 in Supporting Information). This was
confirmed in murine in vivo pharmacokinetics studies with plasma
concentrations of iPEPCK-2 measurable after 15min of administration
and maintained for 8 h, with a Cmax (0.86 μg/mL or 1405 nM) at 30min
and t1/2β at around 2 h (Fig. 1D). The narrow differences in AUC0t and
AUC0∞ showed complete exposure and good bioavailability of iPEPCK-
2 after intraperitoneal administration in the described conditions.
iPEPCK-2 was not found in the brain at the working concentrations,
suggesting that the compound did not cross the blood brain barrier. We
classified iPEPCK-2 as to have uncertain BBB permeation based on data
from in vitro PAMPA assays (Pe value of 2.6 ± 0.2; see Table S2 in
Supporting Information). No additional warning on toxicity were
measured on cell viability assays in human MRC-5 fibroblast at 100 μM
or on hERG inhibition (see Table S3 in Supporting Information). Fi-
nally, we found that iPEPCK-2 has acceptable solubility (61 μM at 37 °C
in 1% DMSO, 99% PBS).
The inhibitory capacity of iPEPCK-2 and 3-MPA, was assayed on
human recombinant PEPCK-C and PEPCK-M produced in our laboratory
(Fig. 2A). iPEPCK-2 was the most potent inhibitor for both isoforms
with an IC50 of 117.4 nM for PEPCK-M and 60.7 nM for the cytosolic
isoform. The capacity to reach the mitochondria and inhibit PEPCK-M
was confirmed using a cellular thermal shift assay (CETSA) (Fig. 2B).
All inhibitors tested thermally stabilized PEPCK-M in live MEF cells,
Fig. 2. iPEPCK-2 activity and target engagement. (A) Inhibition of purified human recombinant PEPCK-C and PEPCK-M by iPEPCK-2 and 3-MPA. IC50 for both
isoforms are noted for every plot. (B) Representative Cellular Thermal Shift Assay (CETSA) at varying concentrations of inhibitors. PEPCK-M specific signal is
detected by western blot in MEF cell extracts after 30min incubation with different concentrations of 3-MPA and iPEPCK-2, prior to thermal treatment at 60 °C. (C)
Calculated isothermal dose response fingerprint (ITDRFCETSA) for both inhibitors. (D) Effects of iPEPCK-2 and 3-MPA on INS1 glucose-stimulated insulin production
shown as a ratio of insulin concentration measured in the presence of 20mM over 3mM glucose. (E) Basal glycemia 5 h after an intraperitoneal administration of 3-
MPA (50mg/kg), iPEPCK-2 (10 or 25mg/kg) or vehicle under fasting conditions. (F) Plasma Insulin at 15min after an administration of a glucose bolus (2 g/kg) in
the presence of inhibitors and vehicle. Data are means ± SEM (3 independent experiments were performed with n≥ 3 in experiments shown in panels A and D; n≥
2 in experiments shown in panels B and C; n=6 in experiments shown in panels E and F). A one-way Anova and a Sidak multiple comparison test was used.
Statistical significance at *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control.
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which express exclusively the PEPCK-M isoform [7], confirming the
accessibility to, and the binding and interaction with PEPCK-M in the
mitochondrial matrix by both inhibitors. The capacity of the inhibitors
to stabilize PEPCK-M against thermal denaturation was dose-depen-
dent. A quantitative evaluation of target engagement at various doses of
inhibitor demonstrated that iPEPCK-2 had the highest affinity for
PEPCK-M, as compared to 3-MPA (ITDRFcetsa, dose of inhibitor
achieving a 50% stabilization at 60°C, was 5.08 vs 303.9 μM for iPEPCK-
2 and 3-MPA, respectively) (Fig. 2C).
To evaluate the capacity of iPEPCK-2 to inhibit PEPCK-M driven
pathways in an in-cell assay where PEPCK-C is not present, we took
advantage of the role of this isoenzyme relaying glucose metabolism
and insulin secretion (GSIS) in pancreatic β-cells or rat insulinoma INS-
1, demonstrated using genetic models and oligonucleotides [5]. We
therefore characterized iPEPCK-2 inhibition efficiency (EC50) in INS-1
cells by quantifying glucose-stimulated insulin production (GSIS) in the
presence of various concentrations of inhibitor. These studies confirmed
that iPEPCK-2 treatment inhibited GSIS in a dose-dependent manner
with an approximate EC50 of 250 nM (Fig. 2D).
To further evaluate the capacity of iPEPCK-2 to antagonize PEPCK
driven pathways, we assayed hepatic gluconeogenesis and insulin se-
cretion in vivo. Hepatic gluconeogenesis in rodents is mainly driven by
PEPCK-C [4,6]. In fasted mice, systemic in vivo glucose production is
assayed in response to a bolus administration of pyruvate. In this set-
ting, glycemia reflects the net contribution of glucose synthesis to
glucose homeostasis. iPEPCK-2 (10 and 25mg/kg) and 3-MPA (50mg/
kg) had a significant negative impact on basal glycemia 5 -hs after ad-
ministration (Fig. 2E), and over the glycemia excursion observed after
the pyruvate bolus (see Fig. S3A–B in Supporting Information), as
compared to DMSO treated mice. These data suggest that 3-MPA and
iPEPCK-2 inhibit hepatic gluconeogenesis in vivo.
Finally, to assess PEPCK-M specific inhibition in vivo, we evaluated
Fig. 3. Target selectivity and validation in cultured cancer cells. (A–C) Proliferation of MCF7 (A), HEK-293 wild-type and PCK2del/del (B) and SW-480 wild-type
and PCK2del/del (C) after a 72-h treatment with iPEPCK-2. (D-F) Cell survival of wild-type MCF7 (D), HEK-293 (E) and SW-480 (F) in glucose-free media after 48 -hs of
treatment with iPEPCK-2. (G) Survival (right panel) and mechanism of apoptotic cell-death (left panel) because of iPEPCK-2 treatment in limiting glucose conditions
in HCT-116 wild-type cells. (H) Colonies formed when MCF7 cells were seeded in soft agar and treated with PEPCK-M inhibitors (5 μM) for 2 weeks. Representative
photographs of 2-week colonies formed in each treatment group are noted. Data are means ± SEM (3 independent experiments were performed with n= 5 in each
experiment shown in panels A thorough F, and plot shown in panel G; 2 independent experiments were performed with n ≥ 2 to produce the representative western
blot shown in panel G; 3 independent experiments were performed with n ≥ 3 to produce panel H plot and representative photographs). A one-way Anova and a
Sidak multiple comparison test was used. Statistical significance at *p < 0.05, **p < 0.01, ***p < 0.001 vs vehicle control.
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Fig. 4. In vivo evaluation of iPEPCK-2 antitumoral activity in two murine subcutaneous xenograft models. (A–B) Over-the-skin tumor volume ([short length2 x
long length]/2) from HEK-293 (A) and SW-480 (B) cells implanted into the flanks of BALB/C nude mice. Once the tumors grew sufficiently large to be measurable,
animals were randomly grouped and daily treated with 8mg/kg of iPEPCK-2 or vehicle intraperitoneally. (C) Representative tumor explants are shown. (D) HEK-293
tumors were weighted at the time of sacrifice. (E–F) Animals growing HEK-293 (E) and SW-480 (F) tumors were weighted periodically over the course of the
experiment to detect health-related issues. (G) Representative H&E stained sections from various organs (liver, kidney, pancreas and spleen) to show no sign of
apparent toxicity. Data are means ± SEM (n=5 in each experiment shown in panels A thorough F, except for HEK-293 control group containing n= 3 due to
animal issues upon tumor over growth; at least n=3 sections per tumor were produced and examined to produced panel G and representative photographs).
M. Aragó, et al. Biomedicine & Pharmacotherapy 121 (2020) 109601
7
pancreatic β-cell secretion of insulin in response to an intraperitoneal
glucose bolus (IGTT). In this assay, glucose-stimulated insulin secretion
generates a peak of plasma insulin concentration after a 2 g/kg glucose
bolus is administered intraperitoneally in fasted mice. The animals for
this test were submitted to inhibitor treatment just 2 -hs before the
glucose bolus to avoid significant effects on basal glycemia (Fig. S3C).
Treatment with iPEPCK-2 (10mg/kg) showed a blunted insulin secre-
tion response to glucose as compared to vehicle and 3-MPA (50mg/kg)
treated mice (Fig. 2F). The dose of iPEPCK-2 utilized confirmed that a
single intraperitoneal administration of 8–10mg/kg was enough to
achieve efficacy, as supported by pharmacokinetic data (Fig. 1D)
showing plasma concentrations of the drug 8 h post-administration al-
ways above the approximate EC50 calculated for insulinoma cells. 3-
MPA reduction of insulin secretion was not statistically significant,
suggesting inefficient target engagement as compared to the successful
targeting of liver PEPCK-C demonstrated in the previous experiment
(Figs. 2E and S3A-B; gluconeogenesis), or a problem to successfully
reach pancreatic β-cells. Therefore, iPEPCK-2 targets PEPCK-M in vivo
in pancreas β-cells, but it is non-selective for the mitochondrial isoform
(Fig. 2D–F).
3.2. Preclinical validation of iPEPCK-2 and its target in cancer indications
PEPCK-M is present in pancreatic β-cells, tumor cells [5,7] and
progenitors (neuroprogenitor cells [8];), hinting at a possible role for
the enzyme in cancer cell metabolic adaptations. Indeed, we and others
have validated this enzyme as a cancer target in several genetic models,
both in vitro and in vivo [7,10–12]. Therefore, we aimed to validate
iPEPCK-2 in a preclinical cancer indication by assaying viability, in-
vasion, and in vivo tumor growth using epithelial MCF7 and HEK-293,
and human colon carcinoma cells from epithelial HCT-116 and me-
senchymal SW-480 origins. These cell lines express high levels of
PEPCK-M and the cytosolic isoform is undetectable (Expression Atlas
RNAseq geneset E-MTAB-2770). To evaluate target selectivity and test
for off-target events, the impact of iPEPCK-2 in tumor cell viability was
also assessed in cells lacking PEPCK-M using knock-out clones of HEK-
293 (HEK-293-PCK2del/del) and SW-480 (SW-480-PCK2del/del) previously
generated in our laboratory using CRISPRCas9 (Fig. S4, and Hyrossova
et al, publication pending).
Treatment with iPEPCK-2 significantly reduced DMSO-normalized
viability in wild type MCF7, HEK-293, and SW-480 cells grown in op-
timal culture conditions (Fig. 3A–C). Changes in viability with iPEPCK-
2 were dependent on the presence of PEPCK-M, since when tested in
HEK-293-PCK2del/del and SW-480-PCK2del/del cells the compound did not
show additional effects beyond those consequence of knocking-out the
gene, at least within the range of iPEPCK-2 (0.1–10 μM) utilized in the
validation assays. All in all, these data suggest target selectivity and a
no significant off-target effects (Fig. 3A–C).
PEPCK-M participates in pro-survival mechanisms engaged by nu-
trient limitation through the ER-stress pathway, and silencing the gene
exacerbates ER-stress-mediated apoptosis [7]. Consistently, PEPCK-M
inhibitors decreased the DMSO-normalized viability of cancer cells
coping with nutrient stress after 48 h of glucose deprivation (Fig. 3D–F).
These effects mimicked the consequences of PEPCK-M loss in HEK-293-
PCK2del/del and SW-480-PCK2del/del when compared to their wild-type
counterparts (Hyrossova et al, publication pending). The inhibition of
PEPCK-M with iPEPCK-2 also copied the response observed in genetic
models by Mendez-Lucas et al, as iPEPCK-2 compromised growth and
enhanced PARP cleavage and apoptosis upon activation of p53 and p21
in HCT-116 cells in limiting glucose conditions (Fig. 3G). A physiolo-
gically relevant model to evaluate the response of cancer cells to dif-
fusion constraints in nutrient supply is colony formation and growth in
an anchorage-independent manner. Anchorage-independent growth
during invasion and metastatic processes is also an important hallmark
in cancer progression. iPEPCK-2 and 3-MPA treatment significantly
reduced MCF7 colony formation when seeded in soft agar (Fig. 3H),
although 3-MPA was less effective. Similar results were obtained in
HCT-116 (data not shown).
We next examined the capacity of inhibitor iPEPCK-2 to blunt tumor
growth in two xenograft murine models. Colon carcinoma (SW-480) or
transformed kidney embryonal cells (HEK-293) cells were sub-
cutaneously injected in both flanks of athymic mice and allowed to
grow until measurable at the surface of the skin. Mice were randomly
split into two different groups treated with a daily intraperitoneal in-
jection of 8mg/kg of iPEPCK-2 or vehicle for a variable period de-
pending on the biological features of each model. Whereas vehicle
treatment did not impede tumor growth, iPEPCK-2 treatment halted
tumor growth in either xenograft mode, as measured both by con-
tinuous evaluation of volume under-the-skin and final weight
(Fig. 4A–D). Histopathology of tumor samples from treated or untreated
breast carcinoma or colon carcinoma tumors showed marked differ-
ences in both groups, with prominent necrosis observed in iPEPCK-2
treated tumors and reduced tumor cell burden overall (quantified in
Fig. S5A–E in Supporting Information). Furthermore, no signs of ap-
parent toxicity were observed upon close inspection; specifically, there
was no macroscopic affectation of the liver or the spleen, weight loss
(Fig. 4E and F), lethargy or major health-related disturbance apparent
on mucosae or skin quality. The histopathological analysis of eosin and
hematoxylin stained tissue sections from different organs did not show
any sign of toxicity (Fig. 4G).
4. Discussion
The dominant role of hepatic PEPCK-C in the imbalance of glucose
homeostasis in obese and diabetic patients [3] has justified the devel-
opment of several low-potency compounds targeting this enzyme in the
past 30–40 years (Jomain Baum et al., 1976), including compounds that
mimic OAA [20], or analogs of 3-MPA [21]. In 2007, Pietranico et al.
[13] described a series of C-8 modifications of xanthine derivatives with
increased potency against PEPCK-C in the context of diabetes indica-
tions, although, it is unclear whether these compounds are being fur-
ther pursued.
Because of recent findings on the mitochondrial isoform, PEPCK-M,
and its impact in cancer biology [22], development of compounds
targeting this pathway for cancer indications has gained new interest.
Based on the sequence identity (69%) and similarity (82%), we hy-
pothesized that PEPCK-C inhibitory compounds described by Pietranico
et al. (synthesized here as iPEPCK-2) would properly dock onto PEPCK-
M, especially since the binding pocket is mostly preserved. Consistently,
the two orientations predicted from docking calculations for the benzyl-
4-sulfonamide-5-chloro-1,3-dimethyl-1H-pyrazole moiety matched the
arrangement found in the crystallographic ligand in 2GMV (on PEPCK-
C), which is characterized by the stacking of the pyrazole ring with the
benzene moiety of F530, with a minor deviation on the second case due
to the interaction of the sulfonamide group with the guanidine moiety
of R570. Notably, this interaction is enabled by the replacement of
G570 in PEPCK-C by R in PEPCK-M, it being one of the few differences
found close to the binding pocket. These data unveil the possibility to
explore selectivity toward PEPCK-M in the future by exploiting the
differences in residues located at the edge of the binding site in the two
isoforms.
Activity assays on recombinant PEPCK-M and PEPCK-C from human
confirmed cross-inhibition by inhibitor iPEPCK-2. IC50 values obtained
in PEPCK-C activity assays were in the expected range [13], and 2-
orders of magnitude lower than 3-MPA [19,23]. Similar potencies were
found for PEPCK-C and PEPCK-M, as can be realized from the resem-
blance of the binding pockets in the two isoforms and the results from
docking calculations. Furthermore, thermal stabilization of PEPCK-M
by iPEPCK-2 presented similar kinetics to PEPCK-C in in-cell conditions,
ruling out that compartmentalization of the mitochondrial isoform
presents a relevant hinder to target engagement. Mitochondrial tar-
geting was functionally demonstrated in rat insulinoma cells (INS-1) by
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asserting the capacity of inhibitor iPEPCK-2 to interfere with glucose-
stimulated insulin secretion in a dose-dependent manner. In the same
model, Stark et al. [5] had shown an identical response using siRNA-
driven down-regulation of PCK2 mRNA, identifying a role for this
protein in the coupling mechanism responsible for insulin secretion
secondary to the metabolism of glucose. Similarly, effective targeting of
PEPCK-M in vivo by iPEPCK-2 was corroborated by a higher than 50%
impact on short-term insulin secretion in fasted mice after an in-
traperitoneal administration of glucose, demonstrating the bioavail-
ability of iPEPCK-2. These data provided the first evidence of PEPCK-M
druggability in this physiological context, and an initial assessment of
iPEPCK-2 usefulness in a pre-clinical setting, as prior data using oli-
gonucleotide silencing of PEPCK-M in rats had not provided evidence
for direct action on the healthy pancreas [24]. Overall, PEPCK-M mo-
lecular and functional target engagement was appropriately demon-
strated both in vitro, in-cell and in vivo.
Once druggability was confirmed, iPEPCK-2 was further validated
as an anticancer strategy starting off by contrasting the consequences of
pharmacological inhibition and genetic ablation using PCK2-KO models
produced using CRISPR/Cas9. Importantly, PCK2-KO cells also allowed
us to demonstrate that the effects on tumor cell growth are PEPCK-M
dependent, since iPEPCK-2 was ineffective at altering growth rates at
concentrations utilized throughout the study in the absence of PEPCK-
M, discarding off-target effects with consequences on tumor biology. In
HEK-293 and SW-480 PEPCK-M inhibition by iPEPCK-2 mimicked ge-
netic down-regulation of PEPCK-M by reducing cell proliferation and
increasing cell death (not shown; Méndez-Lucas et al., 2014). Finally,
even though PEPCK-C has been also implicated in metabolic adapta-
tions specifically in melanoma [25], the participation of this isozyme in
some of the effects observed here can be ruled-out as all cancer cell
lines utilized in the present study have null expression of this isoform
(Expression Atlas RNAseq geneset E-MTAB-2770). All-in-all, these data
suggest that PEPCK-M is the plausible target for iPEPCK-2 in tumor cells
at the concentrations tested.
Its potential as anticancer target resides in the capacity of PEPCK-M
to flux glutamine carbons entering the TCA towards the glycolytic pool
for the synthesis or serine/glycine, especially under nutrient depriva-
tion, balancing ER stress and increasing cell survival [6,7,10]. This is
exemplified in the marked effects observed after PEPCK-M inhibition in
anchorage-independent growth in soft-agar, further validating PEPCK-
M role in tumor cell metabolism, but also in invasiveness and metas-
tasis. This idea was reinforced in vivo where both xenografted tumors
stalled by daily administration of iPEPCK-2 as compared with vehicle.
Reduced tumor growth confirmed that PEPCK-M expression offers a
growth advantage to cancer cells and its inhibition could be a useful
anticancer strategy. Pharmacokinetics profile and good bioavailability,
with no crossing of the BBB, are good starting grounds for the pro-
spective use of this compound in further clinical testing. Importantly,
possible toxicity issues secondary to the inhibition of liver PEPCK-C or
pancreatic PEPCK-M were not substantiated in xenografted mice by our
limited evaluation of liver histology, weight gain or other health related
signs, or changes in plasma insulin or glucose (Fig. S5F–G). Besides,
insulin being a well-known growth factor, reduced insulinemia could
work in synergy with PEPCK-M inhibition in the tumor. However, a full-
blown toxicity assessment will be required to confirm these claims in
the future.
In summary, we report here the first validation of a compound that
target PEPCK-M as cancer therapeutics. PEPCK-M’s crucial role in
conditions of glucose limitation are accompanied by the capacity of the
pathway to balance ER-stress and amino acid availability to warrant the
anticancer effectiveness of iPEPCK-2 in our xenografted models. Hence,
PEPCK-M is an exceptional element of the tumor metabolic toolbox to
cope with huge variations in nutrient and metabolite availability in the
heterogenous tumor. As clinical evidence mounts on the relevance of
targeting metabolic enzymes for cancer therapy, it is indeed becoming
clearer that pursuing key tumor metabolic hallmarks such as glycolysis
or glutamine addiction might not be enough in the long run [26].
Therefore, a double-sword strategy, where PEPCK-M is one of the hits,
might be ideal to deal with the demonstrated metabolic flexibility of
tumors cells.
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